Liu Xiangdong, Li Wei, Zhou Jie
Department of Oncology, Bijie Cancer Hospital, Bijie, China.
Department of Integrated Traditional Chinese and Western Medicine, Bijie Cancer Hospital, Bijie, China.
Front Med (Lausanne). 2025 Jun 25;12:1621425. doi: 10.3389/fmed.2025.1621425. eCollection 2025.
This study aimed to explore the effects of intensity-modulated radiation therapy (IMRT) combined with microwave diathermy (MWD) on tumor marker levels and prognosis in patients with cervical cancer.
A retrospective analysis was conducted on the clinical data of 121 cervical cancer patients admitted to our hospital from April 2021 to April 2023. Among them, 59 patients received IMRT alone (IMRT group), while 62 patients received IMRT combined with MWD treatment (combination group). Comparison of disease control rates, serum tumor marker levels before and after treatment, quality of life (QoL), and prognosis between the two groups.
The combination group achieved a significantly higher disease control rate (88.71%) than the IMRT group (74.58%). After treatment, serum levels of carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCCA), and carbohydrate antigen 50 (CA50) were significantly lower in the combination group than in the IMRT group ( < 0.05). Similarly, after treatment, serum levels of transforming growth factor- (TGF-β), basic fibroblast growth factor (bEGF), and high-mobility protein A1 (HMGA1) were significantly reduced in the combination group than in the IMRT group ( < 0.05). After treatment, the improvement in the QoL in the combination group was significantly higher than that in the IMRT group ( < 0.05). Furthermore, the local recurrence rate (3.23%) and distant metastasis rate (1.61%) in the combination group were lower than those observed in the IMRT group (13.56% for both; < 0.05).
Compared to IMRT alone, the combination of IMRT and MWD treatment for cervical cancer patients can significantly downregulate tumor markers and levels of TGF-, bEGF, and HMGA1, increase tumor control effectiveness and patient QoL, and improve disease prognosis.
本研究旨在探讨调强放射治疗(IMRT)联合微波透热疗法(MWD)对宫颈癌患者肿瘤标志物水平及预后的影响。
对2021年4月至2023年4月我院收治的121例宫颈癌患者的临床资料进行回顾性分析。其中,59例患者仅接受IMRT治疗(IMRT组),62例患者接受IMRT联合MWD治疗(联合组)。比较两组的疾病控制率、治疗前后血清肿瘤标志物水平、生活质量(QoL)及预后。
联合组的疾病控制率(88.71%)显著高于IMRT组(74.58%)。治疗后,联合组血清癌胚抗原(CEA)、鳞状细胞癌抗原(SCCA)和糖类抗原50(CA50)水平显著低于IMRT组(P<0.05)。同样,治疗后,联合组血清转化生长因子-β(TGF-β)、碱性成纤维细胞生长因子(bEGF)和高迁移率族蛋白A1(HMGA1)水平显著低于IMRT组(P<0.05)。治疗后,联合组QoL的改善显著高于IMRT组(P<0.05)。此外,联合组的局部复发率(3.23%)和远处转移率(1.61%)低于IMRT组(均为13.56%;P<0.05)。
与单纯IMRT相比,IMRT联合MWD治疗宫颈癌患者可显著下调肿瘤标志物及TGF-β、bEGF和HMGA1水平,提高肿瘤控制效果和患者QoL,改善疾病预后。